Dataset from A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)

The primary objective of this study is: - To evaluate the effect of DN-101 in combination with docetaxel (ASCENT regimen) on survival in metastatic androgen-independent prostate cancer The secondary objectives of this study are: - To determine the effect of the ASCENT regimen on the rate of thromboembolic events (blood clots) - To determine the effect of the ASCENT regimen on prevention of skeletal-related events (fractures) - A Separate sub-study will be conducted at selected study sites in North America to determine the population PK of DN-101.